Conceitos Básicos
Adjuvant treatment for stage III melanoma may not improve overall survival.
Resumo
The content discusses the lack of overall survival benefit from adjuvant treatment for stage III melanoma based on a review of cases in Sweden from 2016 to 2020. The study compared patients before and after the approval of adjuvant treatments and found no significant difference in overall survival rates. Experts suggest the need for better tools to identify patients who may benefit from adjuvant treatment.
Key Highlights:
- Adjuvant treatment is standard practice for stage III melanoma.
- No improvement in overall survival was observed in Swedish cases.
- Phase III trials have not reported overall survival data.
- Experts emphasize the need for further studies and better patient selection tools.
Estatísticas
"Two-year OS rates were 84.3% in the pre-approval group vs 86.1% in the post-approval cohort."
"The study was powered to detect a 2-year survival difference of 5% or more."
Citações
"We believe that this finding is of potential interest to the melanoma community."
"If further studies confirm that there is no long-term impact on overall survival, certainly these adjuvant therapies need to be reconsidered as a standardized recommendation."